Akeso’s ivonescimab delivered a statistically significant overall survival improvement in a Phase 3 lung cancer regimen presented at ASCO. In interim data from the Harmoni-6 trial in China, ivonescimab plus chemotherapy reduced the risk of death versus a PD-1 inhibitor plus chemotherapy comparator, with a reported 34% improvement and a p-value of 0.0017. The study evaluated ivonescimab in previously untreated, advanced squamous non-small cell lung cancer, addressing prior uncertainty around whether VEGF-targeting could translate into an OS benefit in the first-line setting. Akeso previously posted progression-free survival benefits in head-to-head studies conducted in China. Industry attention now shifts to how the regimen’s survival signal compares with existing standards across patient subgroups and what additional follow-up data could clarify for global development and potential regulatory submissions.